Pulmatrix Goodwill and Intangible Assets 2014-2025 | PULM

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Pulmatrix goodwill and intangible assets from 2014 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Pulmatrix goodwill and intangible assets from 2014 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$228.5B
Amgen (AMGN)	$165.9B
Gilead Sciences (GILD)	$140.8B
Vertex Pharmaceuticals (VRTX)	$121.3B
Bristol Myers Squibb (BMY)	$99.6B
CSL (CSLLY)	$86.2B
GSK (GSK)	$78.3B
Regeneron Pharmaceuticals (REGN)	$61B
Alnylam Pharmaceuticals (ALNY)	$42.8B
Argenex SE (ARGX)	$36.2B
BioNTech SE (BNTX)	$27.5B
Royalty Pharma (RPRX)	$20.6B
Insmed (INSM)	$19.6B
Biogen (BIIB)	$19.4B
Illumina (ILMN)	$17B
Genmab (GMAB)	$15.2B
Genmab (GNMSF)	$14.9B
Incyte (INCY)	$13.6B
Moderna (MRNA)	$13.2B
Exelixis (EXEL)	$12.2B
BioMarin Pharmaceutical (BMRN)	$11.5B
QIAGEN (QGEN)	$11.4B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10.3B
Exact Sciences (EXAS)	$9.2B
Bio-Techne Corp (TECH)	$9.2B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Blueprint Medicines (BPMC)	$8.3B
Legend Biotech (LEGN)	$8.1B
Roivant Sciences (ROIV)	$7.7B